Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariants.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
14 07 2023
Historique:
received: 12 12 2022
accepted: 03 07 2023
medline: 17 7 2023
pubmed: 15 7 2023
entrez: 14 7 2023
Statut: epublish

Résumé

SARS-CoV-2 Omicron subvariants have evolved to evade receptor-binding site (RBS) antibodies that exist in diverse individuals as public antibody clones. We rationally selected RBS antibodies resilient to mutations in emerging Omicron subvariants. Y489 was identified as a site of virus vulnerability and a common footprint of broadly neutralizing antibodies against the subvariants. Multiple Y489-binding antibodies were encoded by public clonotypes and additionally recognized F486, potentially accounting for the emergence of Omicron subvariants harboring the F486V mutation. However, a subclass of antibodies broadly neutralized BA.4/BA.5 variants via hydrophobic binding sites of rare clonotypes along with high mutation-resilience under escape mutation screening. A computationally designed antibody based on one of the Y489-binding antibodies, NIV-10/FD03, was able to bind XBB with any 486 mutation and neutralized XBB.1.5. The structural basis for the mutation-resilience of this Y489-binding antibody group may provide important insights into the design of therapeutics resistant to viral escape.

Identifiants

pubmed: 37452031
doi: 10.1038/s41467-023-39890-8
pii: 10.1038/s41467-023-39890-8
pmc: PMC10349087
doi:

Substances chimiques

Antibodies, Viral 0
Broadly Neutralizing Antibodies 0
Antibodies, Neutralizing 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4198

Informations de copyright

© 2023. The Author(s).

Références

Acta Crystallogr D Biol Crystallogr. 2006 Jan;62(Pt 1):72-82
pubmed: 16369096
Lancet Infect Dis. 2023 Mar;23(3):280-281
pubmed: 36736338
Nat Methods. 2017 Mar;14(3):290-296
pubmed: 28165473
Science. 2021 Feb 19;371(6531):823-829
pubmed: 33495307
Patterns (N Y). 2021 Dec 09;3(2):100406
pubmed: 35199061
Science. 2020 Aug 21;369(6506):1014-1018
pubmed: 32540904
J Comput Chem. 2009 Jul 30;30(10):1545-614
pubmed: 19444816
Nat Commun. 2021 Jun 21;12(1):3802
pubmed: 34155214
Immunity. 2021 Aug 10;54(8):1841-1852.e4
pubmed: 34246326
Acta Crystallogr D Struct Biol. 2019 Oct 1;75(Pt 10):861-877
pubmed: 31588918
J Mol Biol. 2003 Aug 1;331(1):281-99
pubmed: 12875852
Nat Methods. 2017 Jan;14(1):71-73
pubmed: 27819658
Med. 2022 Apr 8;3(4):262-268.e4
pubmed: 35313451
Immunity. 2018 Jan 16;48(1):174-184.e9
pubmed: 29343437
Protein Sci. 2018 Jan;27(1):293-315
pubmed: 29067766
Bioinformatics. 2016 Aug 15;32(16):2451-6
pubmed: 27153634
Nat Rev Immunol. 2023 Mar;23(3):189-199
pubmed: 36168054
J Virol. 2004 Sep;78(17):9007-15
pubmed: 15308697
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):235-42
pubmed: 21460441
Science. 2022 Jan 28;375(6579):449-454
pubmed: 34990214
Sci Transl Med. 2022 Jun 22;14(650):eabn7737
pubmed: 35471044
Cell. 2022 Jul 7;185(14):2422-2433.e13
pubmed: 35772405
Science. 2021 Aug 13;373(6556):
pubmed: 34210892
Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):264-9
pubmed: 23175789
Lancet Infect Dis. 2023 Mar;23(3):278-280
pubmed: 36746173
Nature. 2022 Feb;602(7898):664-670
pubmed: 35016195
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Sci Immunol. 2022 Apr 22;7(70):eabn8590
pubmed: 35113654
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Biophys Rev. 2020 Apr;12(2):371-375
pubmed: 32026396
Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):11937-42
pubmed: 19571001
Nature. 2022 Aug;608(7923):593-602
pubmed: 35714668
PLoS Pathog. 2022 Nov 18;18(11):e1010951
pubmed: 36399443
Cell. 2021 Apr 15;184(8):2183-2200.e22
pubmed: 33756110
Nature. 2021 Aug;596(7873):583-589
pubmed: 34265844
Immunity. 2022 Jun 14;55(6):925-944
pubmed: 35623355
Biophys J. 2015 Oct 20;109(8):1528-32
pubmed: 26488642
J Immunol Methods. 2008 Jan 1;329(1-2):112-24
pubmed: 17996249
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Science. 2020 Nov 20;370(6519):950-957
pubmed: 32972994
Cell. 2022 Jun 9;185(12):2116-2131.e18
pubmed: 35662412
Cell. 2020 Sep 3;182(5):1295-1310.e20
pubmed: 32841599
Bioinformatics. 2021 Oct 25;37(20):3657-3659
pubmed: 33822884
Elife. 2018 Nov 09;7:
pubmed: 30412051
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32
pubmed: 20124692
Nat Immunol. 2022 Jul;23(7):1008-1020
pubmed: 35761083
Nat Commun. 2022 Jun 13;13(1):3375
pubmed: 35697673
Nature. 2022 Aug;608(7923):603-608
pubmed: 35790190
Virol J. 2021 Jan 12;18(1):16
pubmed: 33435994
Nature. 2020 Dec;588(7839):682-687
pubmed: 33045718
Sci Adv. 2021 Feb 17;7(8):
pubmed: 33597251
MAbs. 2022 Jan-Dec;14(1):2072455
pubmed: 35543180
Lancet Infect Dis. 2022 Dec;22(12):1666-1668
pubmed: 36328002
PLoS One. 2013;8(4):e59004
pubmed: 23565140
PLoS One. 2020 Sep 18;15(9):e0239403
pubmed: 32946527
Nature. 2022 Feb;602(7898):676-681
pubmed: 35016198
Proteins. 2021 Apr;89(4):436-449
pubmed: 33249652
Nat Rev Microbiol. 2023 Mar;21(3):162-177
pubmed: 36653446
Nature. 2022 Jul;607(7917):119-127
pubmed: 35576972
Cell. 2020 Aug 20;182(4):828-842.e16
pubmed: 32645326
Nat Methods. 2020 Jul;17(7):665-680
pubmed: 32483333
Immunity. 2021 Oct 12;54(10):2385-2398.e10
pubmed: 34508662
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Protein Sci. 2018 Jan;27(1):14-25
pubmed: 28710774

Auteurs

Saya Moriyama (S)

Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases; Shinjuku-ku, Tokyo, 162-8640, Japan. sayamrym@niid.go.jp.

Yuki Anraku (Y)

Laboratory of Biomolecular Science, and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University; Sapporo, Hokkaido, 060-0812, Japan.

Shunta Taminishi (S)

Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine; Kyoto, Kyoto, 602-8566, Japan.

Yu Adachi (Y)

Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases; Shinjuku-ku, Tokyo, 162-8640, Japan.

Daisuke Kuroda (D)

Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases; Shinjuku-ku, Tokyo, 162-8640, Japan.

Shunsuke Kita (S)

Laboratory of Biomolecular Science, and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University; Sapporo, Hokkaido, 060-0812, Japan.

Yusuke Higuchi (Y)

Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine; Kyoto, Kyoto, 602-8566, Japan.

Yuhei Kirita (Y)

Department of Nephrology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine; Kyoto, Kyoto, 602-8566, Japan.

Ryutaro Kotaki (R)

Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases; Shinjuku-ku, Tokyo, 162-8640, Japan.

Keisuke Tonouchi (K)

Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases; Shinjuku-ku, Tokyo, 162-8640, Japan.
Department of Life Science and Medical Bioscience, Waseda University; Shinjuku-ku, Tokyo, 162-8480, Japan.

Kohei Yumoto (K)

Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases; Shinjuku-ku, Tokyo, 162-8640, Japan.

Tateki Suzuki (T)

Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University; Kyoto, Kyoto, 606-8507, Japan.

Taiyou Someya (T)

Laboratory of Biomolecular Science, and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University; Sapporo, Hokkaido, 060-0812, Japan.

Hideo Fukuhara (H)

Division of Pathogen Structure, International Institute for Zoonosis Control, Hokkaido University, Sapporo, 001-0020, Japan.

Yudai Kuroda (Y)

Department of Veterinary Science, National Institute of Infectious Diseases; Shinjuku-ku, Tokyo, 162-8640, Japan.

Tsukasa Yamamoto (T)

Department of Veterinary Science, National Institute of Infectious Diseases; Shinjuku-ku, Tokyo, 162-8640, Japan.

Taishi Onodera (T)

Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases; Shinjuku-ku, Tokyo, 162-8640, Japan.

Shuetsu Fukushi (S)

Department of Virology I, National Institute of Infectious Diseases; Shinjuku-ku, Tokyo, 162-8640, Japan.

Ken Maeda (K)

Department of Veterinary Science, National Institute of Infectious Diseases; Shinjuku-ku, Tokyo, 162-8640, Japan.

Fukumi Nakamura-Uchiyama (F)

Department of Infectious Diseases, Tokyo Metropolitan Bokutoh Hospital; Sumida-ku, Tokyo, 130-8575, Japan.

Takao Hashiguchi (T)

Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University; Kyoto, Kyoto, 606-8507, Japan.

Atsushi Hoshino (A)

Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine; Kyoto, Kyoto, 602-8566, Japan.

Katsumi Maenaka (K)

Laboratory of Biomolecular Science, and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University; Sapporo, Hokkaido, 060-0812, Japan.
Division of Pathogen Structure, International Institute for Zoonosis Control, Hokkaido University, Sapporo, 001-0020, Japan.
Global Station for Biosurfaces and Drug Discovery, Hokkaido University; Sapporo, Hokkaido, 060-0812, Japan.
Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University; Sapporo, Hokkaido, 060-0812, Japan.

Yoshimasa Takahashi (Y)

Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases; Shinjuku-ku, Tokyo, 162-8640, Japan. ytakahas@niid.go.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH